Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack on mRNA technology.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...